Siloton Secures €9.98 Million Innovate UK Contract to Advance Handheld Eye Imaging Technology

The contract was awarded by Innovate UK, part of UK Research and Innovation (UKRI), through its Contracts for Innovation: Quantum Missions Primer initiative. The programme supports the development of new technologies that address complex challenges faced by public sector organisations.

Alasdair Price, CEO of Siloton, said, “Winning this Innovate UK contract allows us to accelerate the development of our systems, explore manufacturing and assembly in the UK, and help a groundbreaking new technology be adopted by the NHS more quickly.

“Many early-stage companies struggle to get beyond the well-known ‘valley of death’ in developing new products – particularly in healthcare – but this will support us through that crucial phase, bringing the Siloton system closer to being in patients’ hands and building a technology that can be used worldwide.”

Founded in April 2020 in Bristol, UK, Siloton is a MedTech startup and a graduate of the Quantum Technologies Enterprise Centre (QTEC) incubator programme. The company aims to make eye scans more accessible so people with eye diseases can get the tests they need, wherever and whenever possible.

Siloton develops compact optical technology for medical imaging using photonic chips and Optical Coherence Tomography (OCT). This technology uses light to create detailed images of the inside of the eye, helping doctors detect and monitor conditions such as age-related macular degeneration and glaucoma. OCT may also help identify signs of other health conditions, including multiple sclerosis, diabetes, and certain types of cancer.

Traditional OCT machines are often large and fragile, meaning they are mainly used in specialist healthcare settings. This can make eye scans harder to access for some patients. Siloton is working to develop smaller, handheld imaging technology that could make these scans more widely available and help doctors monitor diseases more easily.

Read Also- Nouscom Raises €120 Million in Series D Funding to Advance Cancer Immunotherapy